Related Experiment Videos
Clodronate and osteoporosis
J A Kanis1, E V McCloskey, M N Beneton
1WHO Collaborating Centre for Metabolic Bone Diseases, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK.
Maturitas
|May 1, 1996
Summary
Clodronate, a bisphosphonate, effectively prevents bone loss in osteoporosis patients, particularly at the lumbar spine. Further studies are needed to confirm its impact on fracture frequency.
Area of Science:
- Pharmacology
- Bone Biology
- Osteoporosis Management
Background:
- Bisphosphonates are crucial for treating bone resorption disorders like Paget's disease and hypercalcemia of malignancy.
- Their efficacy and safety profile make them suitable for osteoporosis management.
- Etidronate, pamidronate, and clodronate are key bisphosphonates, with clodronate offering oral and IV administration options.
Purpose of the Study:
- To evaluate clodronate's efficacy in managing osteoporosis and preventing bone loss.
- To compare clodronate with other bisphosphonates regarding bone mineralization and administration routes.
Main Methods:
- Review of existing short-term and long-term studies on clodronate's effects on bone resorption.
- Assessment of clodronate's impact on bone mineral density at the lumbar spine in osteoporotic patients.
Main Results:
- Clodronate inhibits experimentally induced bone resorption and prevents menopausal and immobilization-related bone loss.
- Studies indicate clodronate halts lumbar spine bone loss in vertebral osteoporosis patients.
- Clodronate does not impair bone mineralization, even at high doses, unlike etidronate.
Conclusions:
- Clodronate is a promising bisphosphonate for long-term osteoporosis management, particularly for preserving lumbar spine bone density.
- Further long-term prospective studies are required to determine clodronate's effect on osteoporotic fracture rates.